Logo image of HEPA

HEPION PHARMACEUTICALS INC (HEPA) Stock Fundamental Analysis

NASDAQ:HEPA - Nasdaq - US4268973025 - Common Stock - Currency: USD

0.1707  -0.02 (-9.2%)

After market: 0.168 0 (-1.58%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to HEPA. HEPA was compared to 194 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of HEPA have multiple concerns. HEPA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

HEPA had negative earnings in the past year.
In the past year HEPA has reported a negative cash flow from operations.
In the past 5 years HEPA always reported negative net income.
In the past 5 years HEPA always reported negative operating cash flow.
HEPA Yearly Net Income VS EBIT VS OCF VS FCFHEPA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

HEPA's Return On Assets of -611.14% is on the low side compared to the rest of the industry. HEPA is outperformed by 97.30% of its industry peers.
Industry RankSector Rank
ROA -611.14%
ROE N/A
ROIC N/A
ROA(3y)-125.76%
ROA(5y)-95.95%
ROE(3y)-266.01%
ROE(5y)-185.66%
ROIC(3y)N/A
ROIC(5y)N/A
HEPA Yearly ROA, ROE, ROICHEPA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800 -1K

1.3 Margins

HEPA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HEPA Yearly Profit, Operating, Gross MarginsHEPA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

1

2. Health

2.1 Basic Checks

HEPA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for HEPA has been increased compared to 5 years ago.
HEPA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
HEPA Yearly Shares OutstandingHEPA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
HEPA Yearly Total Debt VS Total AssetsHEPA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -111.11, we must say that HEPA is in the distress zone and has some risk of bankruptcy.
HEPA's Altman-Z score of -111.11 is on the low side compared to the rest of the industry. HEPA is outperformed by 95.68% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -111.11
ROIC/WACCN/A
WACCN/A
HEPA Yearly LT Debt VS Equity VS FCFHEPA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

HEPA has a Current Ratio of 1.30. This is a normal value and indicates that HEPA is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.30, HEPA is not doing good in the industry: 81.08% of the companies in the same industry are doing better.
A Quick Ratio of 1.30 indicates that HEPA should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.30, HEPA is not doing good in the industry: 73.51% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 1.3
HEPA Yearly Current Assets VS Current LiabilitesHEPA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

HEPA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.41%.
EPS 1Y (TTM)-4.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

HEPA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.01% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y5.37%
EPS Next 2Y25.28%
EPS Next 3Y13.6%
EPS Next 5Y10.01%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HEPA Yearly Revenue VS EstimatesHEPA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
HEPA Yearly EPS VS EstimatesHEPA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 -500 -1K -1.5K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

HEPA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HEPA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HEPA Price Earnings VS Forward Price EarningsHEPA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HEPA Per share dataHEPA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -2 -4 -6 -8 -10

4.3 Compensation for Growth

HEPA's earnings are expected to grow with 13.60% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.28%
EPS Next 3Y13.6%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HEPA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HEPION PHARMACEUTICALS INC

NASDAQ:HEPA (2/21/2025, 8:25:23 PM)

After market: 0.168 0 (-1.58%)

0.1707

-0.02 (-9.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-18 2024-11-18/amc
Earnings (Next)04-14 2025-04-14/amc
Inst Owners14.53%
Inst Owner Change-8.53%
Ins Owners0.01%
Ins Owner Change0%
Market Cap1.19M
Analysts82.86
Price Target30.6 (17826.19%)
Short Float %45.92%
Short Ratio0.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-12.32
EYN/A
EPS(NY)-5.3
Fwd EYN/A
FCF(TTM)-3.75
FCFYN/A
OCF(TTM)-3.74
OCFYN/A
SpS0
BVpS-0.06
TBVpS-0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -611.14%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-125.76%
ROA(5y)-95.95%
ROE(3y)-266.01%
ROE(5y)-185.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.3
Quick Ratio 1.3
Altman-Z -111.11
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)63.58%
Cap/Depr(5y)131.48%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.57%
EPS Next Y5.37%
EPS Next 2Y25.28%
EPS Next 3Y13.6%
EPS Next 5Y10.01%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y44.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.57%
OCF growth 3YN/A
OCF growth 5YN/A